PHSC 4340 Lecture Notes - Lecture 5: Ductus Arteriosus, Nonallergic Rhinitis, Hyperkalemia

• School: Northeastern University
• Department: Pharmaceutical Science
• Course: PHSC 4340
• Professor: Boisse Norman

Document Summary

Classical non-selective nsaids: aspirin (asa, ibuprofen & most nsaids. Cox-ii inhibitors: celecoxib (celerex) approved 1998, rofecoxib (vioxx) approved 1999 withdrawn 2004, valdecoxib (bextra) approved 2001 withdrawn 2005. Drugs to treat gout: colchicine, xanthine oxidase inhibitors. Clinical signs: erythema, edema, tenderness, pain. Acute inflammation (transient: initial response to injury; local vasodilation, increased capillary permeability, caused by release of autacoids; pg"s, his, 5-ht, bradykinin, lk. Immune response (delayed, subacute phase: infiltration of leukocytes & phagocytic cells, outcome beneficial (phagocytosis of foreign organisms or deleterious (no resolution) Chronic inflammation (chronic proliferative stage: tissue degeneration & fibrosis, more autacoids; il-1, il-2, il-3, gm-csf, tnf-(alpha), interferons, pdgh, leukocytes release lysosomal enzymes, best example; chronic rheumatic arthritis; bone & cartilage pain and destruction. Pathogenesis unknown: autoimmune disease, cytokine release; il-1, tnf-(alpha) Only glucocorticoids block synthesis or actions: pge2 elevated in inflamed joints due to induction of cox-ii. See figure 24-1 on p. 402 in textbook by aschenbrenner et.